Company intelligence / Profile preview

NW PharmaTech

London, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

NW PharmaTech is advancing multiple clinical programs targeting CNS indications and psychiatric disorders. Its lead program, an oral formulation of cannabidiol developed via OralTransTM technology, is set for late-stage Phase II trials. The company has established strategic joint ventures and employs translational research to overcome traditional bioavailability and delivery challenges associated with natural compounds

Therapeutic areas: NeurologyPsychiatry
Modalities: Small moleculeBiologicCannabinoid (CBD-based drug formulations)
Industry: Biotech

Drug pipeline

1 asset

NWPT-SM32300

Unknown

Partnerships

Satellos Bioscience / Amphotericin B Technologies Inc.; collaborative development and licensing of OralTransTM platform for Oral CBD

Beyond the preview

Go deeper on NW PharmaTech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NW PharmaTech.

Explore the full profile